Bullish
Pfizer's TUKYSA regimen approved for front-line HER2+ breast cancer treatment
Pfizer's TUKYSA regimen has received FDA approval as a front-line maintenance treatment for HER2-positive metastatic breast cancer. This approval is expected to enhance Pfizer's oncology portfolio and potentially boost revenue from cancer therapies.
Key points
- FDA approves TUKYSA regimen for front-line HER2+ breast cancer treatment.
- Pfizer declares $0.43 fourth-quarter 2026 dividend.
- Scotiabank raises Pfizer's price target to $33 from $30.
Sources
- Pfizer’s TUKYSA Regimen Receives FDA Approval as Front-Line Maintenance Treatment for HER2+ Metastatic Breast CancerBusiness Wire · October 7, 2026
- Pfizer Declares Fourth-Quarter 2026 DividendBusiness Wire · October 6, 2026
- Pfizer price target raised to $33 from $30 at ScotiabankTheFly · October 7, 2026
AI-generated from public news sources. Not financial advice.
